deltatrials
Completed PHASE3 NCT00291187

VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study to Investigate the Efficacy and Safety of VEC-162 and Matching Placebo in Healthy Male and Female Subjects With Induced Transient Insomnia

Sponsor: Vanda Pharmaceuticals

Conditions Insomnia
Interventions 100 mg VEC-162 20 mg VEC-162 50 mg VEC-162 Placebo
Updated 6 times since 2017 Last updated: Oct 8, 2014 Started: Feb 28, 2006 Primary completion: Aug 31, 2006 Completion: Aug 31, 2006

A PHASE3 clinical study on Insomnia, this trial is completed. The trial is conducted by Vanda Pharmaceuticals and has accumulated 6 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Feb 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Vanda Pharmaceuticals
Data source: Vanda Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States, Austin, United States, Birmingham, United States, Chevy Chase, United States, Cincinnati, United States, Columbia, United States, Miami, United States, Naples, United States, New York, United States, Overland Park, United States and 9 more location s